Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02240680) looked at a medicine called linagliptin (5 mg) compared to a placebo (a dummy tablet with no active ingredient) in people with type 2 diabetes. The main thing being measured was a blood marker called HbA1c — a percentage that reflects average blood sugar levels over roughly three months, where a higher number generally means blood sugar has been less well controlled. In the first part of the trial (up to 24 weeks), 151 people were assigned to placebo and 151 to linagliptin. A separate group of Japanese participants (50 on placebo, 52 on linagliptin) continued for up to 52 weeks. The reported data shows that, after 24 weeks, the placebo group's HbA1c level fell by an average of 0.38 percentage points from where it started, while the linagliptin group's fell by an average of 1.01 percentage points. For fasting blood sugar (a single blood sugar reading taken after not eating overnight, measured in milligrams per decilitre), the placebo group saw an average change of +0.2 and the linagliptin group saw an average change of −11.3. The reported data also shows that after 24 weeks, about 70% of people in the linagliptin group had an HbA1c below 8%, compared with about 40% in the placebo group; and roughly 38% of the linagliptin group had an HbA1c below 7%, compared with about 15% in the placebo group. Regarding low blood sugar episodes (called hypoglycaemia — when blood sugar drops to a level that can cause symptoms or need assistance), the reported data shows that approximately 30.9% of people in the linagliptin group and 23.8% in the placebo group experienced at least one episode meeting the trial's definition. Using a stricter definition (blood sugar below 54 mg/dL), the figures were 16.8% for linagliptin and 15.0% for placebo. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 31482511) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Type 2 Diabetes Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be willing to sign a consent form agreeing to take part in the trial before any assessments begin.
- You must have been diagnosed with Type 2 Diabetes.
- You must be 60 years of age or older when you sign the consent form.
- You must have been taking a stable dose of a long-acting (basal) insulin for at least 4 weeks before joining, with only small dose changes (up to 20% either way) allowed.
- You may or may not be taking metformin, but if you are, your dose must have been stable for at least 12 weeks before joining.
- You may or may not be taking certain diabetes tablets called alpha-glucosidase inhibitors (such as acarbose), but if you are, your dose must have been stable for at least 12 weeks before joining.
- Your HbA1c (a blood test that shows average blood sugar levels over time) must be between 7.0% and 10.0% at your first visit.
- Your BMI (a measure of body weight relative to height) must be 45 or below at your first visit.
- In the opinion of the trial doctor, you must be willing and able to follow all trial requirements reliably.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have significant difficulties with memory or thinking, based on a mental status test given at the first visit.
- People showing signs of depression, based on a questionnaire score of 10 or more at the first visit.
- People who have Type 1 Diabetes (rather than Type 2).
- People who have had a heart attack, unstable chest pain, stroke, or mini-stroke (TIA) within the 3 months before their first visit.
- People whose liver blood tests show results more than 3 times higher than normal at the screening or run-in stage.
- People who have had weight-loss surgery (such as gastric bypass or gastric banding) within the past 2 years.
- People who have had cancer or received cancer treatment within the last 5 years (skin cancers that were fully removed and were not invasive may be an exception — confirm with trial site).
- People who have certain blood disorders that affect red blood cells, such as haemolytic anaemia, malaria, or babesiosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Boehringer Ingelheim, Boehringer Ingelheim
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 3 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.
Other options
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.